NEW YORK (GenomeWeb News) – British molecular diagnostics company Myconostica has raised £1 million ($1.98 million) to close out a round of Series C financing, according to Amphion Innovations, which owns around 23 percent of the firm.

 

Myconostica is a University of Manchester spin-out that is developing a molecular diagnostic test for life-threatening fungal infections. It has raised a total of £5.4 million ($10.7 million) in the Series C round, Amphion said.